◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Spyre Therapeutics Inc. (SYRE) EBITDA 2014–TTM

Name: Spyre Therapeutics Inc. (SYRE) ebitda history 2014-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-16

Spyre Therapeutics Inc. annual ebitda for fiscal TTM was -$201 million, an increase of 4.3% from -$210 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

SYRE Annual EBITDA

EBITDA (annual)	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31
EBITDA	($201M)	($210M)	($208M)	($242M)	($82M)	($64M)	($79M)	($77M)	($45M)	($27M)	($22M)	($11M)	($10M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SYRE Quarterly EBITDA

EBITDA (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
EBITDA	—	($76M)	($63M)	($11M)	($52M)	($45M)	($56M)	($69M)	($39M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EBITDA at Comparable Companies

PTGX EBITDA — Protagonist Therapeutics Inc
KRYS EBITDA — Krystal Biotech Inc
KYMR EBITDA — Kymera Therapeutics Inc
IONS EBITDA — Ionis Pharmaceuticals Inc
CRNX EBITDA — Crinetics Pharmaceuticals Inc
PCVX EBITDA — Vaxcyte Inc

More SYRE metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding

All SYRE financial statements → Interactive SYRE charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.